Literature DB >> 8778156

Effect of two beta 2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis.

A Giustina1, M Malerba, E Bresciani, P Desenzani, M Licini, G Zaltieri, V Grassi.   

Abstract

The aim of our study was to evaluate the effect of the iv administration of two different beta 2- receptors agonists, salbutamol and broxaterol, on the growth hormone (GH) response to maximal exercise in 11 patients (8 males and 3 females; age range 18-65 yr; mean +/- SE age 56 +/- 13 yr; BMI 26.2 +/- 1.4 kg/m2) with chronic asthmatic bronchitis. All the subjects underwent four cycloergometric exercise tests (incremental workload until maximal predicted heart rate). At baseline, at maximal exercise, at the end of the recovery period and 60 min after the end of each exercise, blood samples were drawn for the assay of GH, glucose, insulin, lactates, norepinephrine and epinephrine. Two exercises were performed without treatment while the remaining two were performed 60 min after the administration of 400 micrograms of either salbutamol or broxaterol (both diluted in 10 ml of saline) according to a randomized double blind cross-over design. Both exercise tests performed without treatment caused a significant (p < 0.05) and similar GH peak with respect to baseline values (from 0.3 +/- 0.1 micrograms/L to 2.8 +/- 1.3 micrograms/L, mean of the two exercise tests). Salbutamol pretreatment blunted the GH response to exercise which caused a no more significant serum GH peak over the baseline levels (from 0.6 +/- 0.2 micrograms/L to 1.4 +/- 0.6 micrograms/L,). Moreover, broxaterol completely abolished the GH response to exercise (baseline level 0.6 +/- 0.2 micrograms/L; peak levels 0.4 +/- 0.1 micrograms/L). The serum GH peak after exercise + broxaterol was significantly (p < 0.05) lower as compared to exercise + salbutamol. In conclusion, we have demonstrated for the first time that beta 2 stimulation blunts the physiological GH response to maximal exercise in adult human subjects. It can be suggested that changes in brain neurotransmitters, possibly an increase in the alpha-adrenergic tone, are likely to be involved in this endocrine effects of exercise.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8778156     DOI: 10.1007/bf03349831

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  29 in total

1.  Beta-adrenergic modulation of growth hormone (GH) autofeedback on sleep-associated and pharmacologically induced GH secretion.

Authors:  M Kelijman; L A Frohman
Journal:  J Clin Endocrinol Metab       Date:  1989-12       Impact factor: 5.958

2.  The hormonal response to exercise.

Authors:  H Galbo
Journal:  Proc Nutr Soc       Date:  1985-07       Impact factor: 6.297

3.  Interaction of salbutamol with pyridostigmine and arginine on both basal and GHRH-stimulated GH secretion in humans.

Authors:  E Ghigo; E Arvat; L Gianotti; J Ramunni; M Maccario; F Camanni
Journal:  Clin Endocrinol (Oxf)       Date:  1994-06       Impact factor: 3.478

4.  Effects of alpha- and Beta-adrenergic agonists and antagonists on growth hormone secretion in man.

Authors:  E Ghigo; J Bellone; E Arvat; E Mazza; S G Cellat; F Brambilla; E E Müller; F Camanni
Journal:  J Neuroendocrinol       Date:  1990-08-01       Impact factor: 3.627

5.  Selective beta 1-adrenergic receptor-blockade with atenolol enhances growth hormone releasing hormone and mediated growth hormone release in man.

Authors:  N Mauras; R M Blizzard; M O Thorner; A D Rogol
Journal:  Metabolism       Date:  1987-04       Impact factor: 8.694

6.  Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy.

Authors:  A Giustina; M G Buffoli; A R Bussi; M Doga; A Girelli; G Pizzocolo; A Pozzi; W B Wehrenberg
Journal:  Horm Metab Res       Date:  1992-05       Impact factor: 2.936

7.  Beta-adrenergic stimulation of growth hormone (GH) release in vivo, and subsequent inhibition of GH-releasing factor-induced GH secretion.

Authors:  R J Krieg; S N Perkins; J H Johnson; J P Rogers; A Arimura; M J Cronin
Journal:  Endocrinology       Date:  1988-02       Impact factor: 4.736

8.  Effect of the combined administration of galanin and clonidine on serum growth hormone levels in normal subjects and in patients under chronic glucocorticoid treatment.

Authors:  A Giustina; S Bossoni; M Licini; C Macca; G Milani; W B Wehrenberg
Journal:  Endocr Res       Date:  1994-05       Impact factor: 1.720

9.  Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children.

Authors:  E Ghigo; M R Valetto; L Gaggero; A Visca; F Valente; J Bellone; D Castello; F Camanni
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

10.  Inhibition of hypothalamic somatostatin release by beta-adrenergic antagonists.

Authors:  S B Richardson; S Twente
Journal:  Endocrinology       Date:  1990-02       Impact factor: 4.736

View more
  2 in total

1.  Effects of acute salbutamol intake during supramaximal exercise in women.

Authors:  Bénédicte Le Panse; Alexandre Arlettaz; Hugues Portier; Anne-Marie Lecoq; Jacques De Ceaurriz; Katia Collomp
Journal:  Br J Sports Med       Date:  2007-01-30       Impact factor: 13.800

2.  Salbutamol intake and substrate oxidation during submaximal exercise.

Authors:  A Arlettaz; B Le Panse; H Portier; A-M Lecoq; R Thomasson; J De Ceaurriz; K Collomp
Journal:  Eur J Appl Physiol       Date:  2008-10-17       Impact factor: 3.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.